Issue 79

Negev Capital and Investing in Psychedelic Healthcare

With US$30 million under its management, Negev Capital is a fund focused on psychedelic drug development, with investments in 20 private and public companies.

Negev Capital is sponsoring the evening reception after PSYCH Symposium: London 2022, for networking opportunities with a community that is ready to support the development of psychedelic healthcare.

Ken Belotsky and Stuart Seidman are partners at the firm and sat down with PSYCH to discuss investment opportunities as stocks continue to fall.

READ MORE

LANDMARK GATHERING OF PSYCHEDELICS EXECUTIVES AND SCIENTISTS IN LONDON

PSYCH Symposium is ‘becoming the focal point for connecting with the European psychedelics industry,’ reports Benzinga.

Read More

THE PSYCHEDELIC GOLD RUSH: MARKETING THE FUTURE OF MENTAL HEALTHCARE

The Drum explores the importance of responsible marketing in psychedelic healthcare.

Read More

BUSINESS AND INVESTMENT

Wesana reports Q4 2021 financial results.

Field Trip to separate into two divisions.

COMPASS announces positive results in studies to treat anorexia nervosa.

Protecting innovations in psychedelic medicines.

Optimi Health opens Canada’s largest psilocybin cultivation facility.

PSYCH Symposium: London 2022

We are only one week away from PSYCH Symposium: London 2022, Europe’s premier psychedelic healthcare conference.

Industry leaders from across the emerging sector are set to converge for exclusive research announcements, regulatory updates and topical discussions, to accelerate access to psychedelic-assisted therapy in Europe.

With only a handful of tickets remaining, register your attendance today to connect with decision makers and contribute to the future of psychedelic medicine.

Speakers include:

  • Amanda Feilding – Beckley Foundation
  • Christian Angermayer – atai Life Sciences
  • Professor David Nutt – Drug Science
REGISTER YOUR TICKET

SCIENCE AND RESEARCH

Is psilocybin the future of mental health treatments?

Why psychedelic medicines may become a key treatment for PTSD and depression.

Lophos looks to reduce peyote’s growth cycle.

Macquarie University to conduct microdosing study.

REGULATION AND LEGISLATION

Colorado bill to legalise MDMA-assisted therapy approved by Senate.

Washington decriminalisation bill has narrow poll lead.

Saskatoon Board of Police Commissioners discusses decriminalisation of drug possession.

Like cannabis, Denver is leading the way with psilocybin legalisation.